Bionaturis Group (ticker BNT), a biotechnology group offering premium solutions for human and animal health, has reported financial results for the Year Ended December 31, 2016 and has provided an update on the Company’s recent developments

According to the global B2B business model of the Group, based on the 4Ps –Products, Portfolio, Platforms and Partnering- it is relevant to note the development portfolio and the license and strategic agreements with third parties as well, highlighting the following achieved milestones:

  • Worldwide and exclusive license agreement with a top leader multinational company for the development and commercialization of SPLITTERA® for the industrial purification of biological products
  • Extension of the Evaluation and Option License Agreement of Zera Subunit Vaccines 2.0 with a leading multinational animal health company to develop biological vaccines
  • Co-development, registration and commercialization license agreement with Ojer Pharma for Mupipet® in Europe
  • Strategic agreement with Labiana Life Sciences to explore joint development options in Animal Health
  • Exclusive license for the development, manufacturing, registration, and commercialization of its Leishmaniasis lead vaccine (BNT005) with the company Laboratorio Biologico de Tandil (Biotandil) for Argentina and Paraguay as the Territory (subsequent event).

Regarding inorganic growth and corporate transactions, during 2016 the Group acquired 100% shares of ZIP Solutions which, adding a highly relevant license agreement on SPLITTERA with a multinational company, along other outstanding high-value assets such as ZERA VACCINES and a board portfolio of international patents.

About Biobide -the CRO business division of the Group- to point out its steady growth and positive performance not only in net sales but also in the broadening of the zebrafish assays portfolio and the number of customers coming from new sectors –in addition to the consolidation of the already existing ones.

On financial updates, Bionaturis Group has increased net sales (+24.9% YoY) and revenues to EUR 3.79 million (+ EUR 1.39 million vs 2015). This new YoY increase means a 11% CAGR in net sales between 2012 and 2016. EBITDA before special items improves to EUR 402 thousand (+ EUR 382 thousand vs 2015), meaning a 29% of EBITDA margin on net sales.

For the official disclosing, please click here (only in Spanish)